Detalle Publicación

Plain language summary of the HIMALAYA study: tremelimumab and durvalumab for unresectable hepatocellular carcinoma (liver cancer)

Autores: Abou-Alfa, G. K. (Autor de correspondencia); Lau, G.; Kudo, M.; Chan, S. L.; Kelley, R. K.; Furuse, J.; Sukeepaisarnjaroen, W.; Kang, Y. K.; Dao, T. V.; De Toni, E. N.; Rimassa, L.; Breder, V.; Vasilyev, A.; Heurgue, A.; Tam, V. C.; Mody, K.; Thungappa, S. C.; Ostapenko, Y.; Yau, T.; Azevedo, S.; Varela, M.; Cheng, A. L.; Qin, S. K.; Galle, P. R.; Ali, S.; Gupta, C.; Makowsky, M.; Kurland, J. F.; Negro, A.; Sangro Gómez-Acebo, Bruno Carlos
Título de la revista: FUTURE ONCOLOGY
ISSN: 1479-6694
Volumen: 19
Número: 38
Páginas: 2505 - 2516
Fecha de publicación: 2023
What is this summary about?: This is a summary of results from a phase 3 clinical study called HIMALAYA. HIMALAYA looked at treatment with one dose of a medication called tremelimumab combined with multiple doses of a medication called durvalumab (the STRIDE regimen) or multiple doses of durvalumab alone. These treatments were compared with a medication called sorafenib in participants with unresectable hepatocellular carcinoma (HCC). HCC is a type of liver cancer that is difficult to treat because it is often diagnosed when it is unresectable, meaning it can no longer be removed with surgery. Sorafenib has been the main treatment for unresectable HCC since 2007. However, people who take sorafenib may experience side effects that can reduce their quality of life, so alternative medicines are being trialed. Tremelimumab and durvalumab are types of drugs called immunotherapies, and they both work in different ways to help the body's immune system fight cancer. What were the results of the study?: Participants who took STRIDE lived longer than participants who took sorafenib, whilst participants who took durvalumab alone lived a similar length of time as participants who took sorafenib. Participants who took STRIDE or durvalumab had a lower relative risk of experiencing worsening in their quality of life than participants who took sorafenib. The side effects that participants who received STRIDE or durvalumab experienced were expected for these types of treatments and could mostly be managed. What do the results of the study mean?: Overall, STRIDE is more effective than sorafenib for people with unresectable HCC.